Luxembourg joins forces with 22 European partners as part of CARDIATEAM, aiming to improve diagnosis and care of a heart disease linked to diabetes.
Type 2 diabetes, which is characterised by hyperglycemia, can contribute to the development of heart disease in 2 ways.
Indirectly, by promoting coronary artery disease or directly through the development of functional and structural abnormalities which cause a dysfunction, known as cardiomyopathy. Its origination and development have not yet been defined and no effective therapy is available.
CARDIATEAM, a five-year public-private partnership between 22 partners, aims to find out how unique diabetic cardiomyopathy is compared to other form of heart failure and whether type 2 diabetes is a central factor in the progression of the disease.
In order to do this, CARDIATEAM recruits 1600 diabetic and non-diabetic patients and collects data on their cardiovascular health over the course of 3 years.
Luxembourg Institute of Health's (LIH) role is to interpret sets of data which will be generated from blood samples. The integrated BioBank of Luxembourg (IBBL) will figure as the central Biobank in the project and collect, store and re-distribute blood samples.
Dr. Yvan Devaux, Head of LIH's Cardiovascular Research Unit says the project will ''increase Luxembourg’s visibility in Europe and consolidate its reputation as a reliable partner in competitive EU-funded studies and public-private partnerships.''